Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson’s disease (PD) by unknown
REVIEW Open Access
Linking F-box protein 7 and parkin to
neuronal degeneration in Parkinson’s
disease (PD)
Zhi Dong Zhou1,3*†, Sushmitha Sathiyamoorthy1†, Dario C. Angeles2 and Eng King Tan1,2,3*
Abstract
Mutations of F-box protein 7 (FBXO7) and Parkin, two proteins in ubiquitin-proteasome system (UPS), are both
implicated in pathogenesis of dopamine (DA) neuron degeneration in Parkinson’s disease (PD). Parkin is a HECT/
RING hybrid ligase that physically receives ubiquitin on its catalytic centre and passes ubiquitin onto its substrates,
whereas FBXO7 is an adaptor protein in Skp-Cullin-F-box (SCF) SCFFBXO7 ubiquitin E3 ligase complex to recognize
substrates and mediate substrates ubiquitination by SCFFBXO7 E3 ligase. Here, we discuss the overlapping
pathophysiologic mechanisms and clinical features linking Parkin and FBXO7 with autosomal recessive PD.
Both proteins play an important role in neuroprotective mitophagy to clear away impaired mitochondria.
Parkin can be recruited to impaired mitochondria whereas cellular stress can promote FBXO7 mitochondrial
translocation. PD-linked FBXO7 can recruit Parkin into damaged mitochondria and facilitate its aggregation.
WT FBXO7, but not PD-linked FBXO7 mutants can rescue DA neuron degeneration in Parkin null Drosophila. A better
understanding of the common pathophysiologic mechanisms of these two proteins could unravel specific pathways
for targeted therapy in PD.
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Background
Parkinson’s disease (PD) is one of the most common
neurodegenerative disorder characterized by chronic and
progressive loss of dopaminergic neurons in substansia
nigra pars compacta (SN). PD can affect about 2 % of
the population above 65 years of age [1–3]. PD symp-
toms include rigidity, postural instability, tremor at rest
and slowness or absence of voluntary movement, and
even neuropsychiatric symptoms [4, 5]. The pathological
hallmarks of PD include progressive degeneration of
dopamine (DA) neurons in SN [5, 6] as well as accumula-
tion of α-synuclein (α-syn) positive Lewy bodies in
afflicted brain regions [7–9]. Although various hypotheses,
including oxidative stress [10], mitochondrial dysfunction
[11, 12], impairment of the ubiquitin proteasome system
(UPS) and defects in autophagy process [1, 4, 11], have
been proposed to be implicated in progressive loss of DA
neurons in PD, the exact mechanisms accounting for DA
neuron demise in PD still remains to be elucidated [13].
Though most PD cases are late onset and may be clas-
sified as sporadic PD (SPD), gene mutations or varia-
tions can lead to early onset inherited familial PD (FPD)
[3, 14]. Accumulative evidence from studies on FPD
have significantly deepened our understanding of PD
pathogenesis [15]. The recessive mutations in Parkin
gene (PARK2) are associated with classic Levodopa re-
sponsive FPD [16]. However recessive gene mutations of
FBXO7 (PARK15) are associated with juvenile onset
Parkinsonism frequently accompanied with atypical fea-
tures including dementia, dystonia, hyperreflexia and
pyramidal signs [17, 18]. Here, we discuss the overlap-
ping pathophysiologic mechanisms and clinical features
linking Parkin and FBXO7 with autosomal recessive PD.
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UPS dysfunction, proteotoxicity and PD pathogenesis
There is increasing evidence to suggest that dysfunction
of UPS plays a major role in PD pathogenesis. The func-
tion of UPS is to target and degrade unneeded or dam-
aged proteins by proteolysis, a chemical reaction that
breaks peptide bonds. The UPS processes involve tar-
geted conjugation of multiple ubiquitin molecules to
protein substrates and subsequent degradation of polyu-
biquitin tagged proteins by proteasome [19]. The process
will finally yield peptides of about seven to eight amino
acids long, which can be further degraded into shorter
amino acid fragments for new proteins synthesis [20]. It
was reported that proteasome inhibition induced UPS
impairment can result in accumulation of misfolded pro-
teins and deleterious protein aggregates, contributing to
neuronal dysfunction and demise [21]. The accumula-
tion of misfolded and aggregated proteins induced tox-
icity is termed as proteotoxicity, which has been found
to be implicated in pathogenesis of various human disor-
ders, including carcinogenesis, neurodegenerative dis-
eases, aging process, cardiovascular disorders, diabetes
and many other human diseases [22–25]. Recent find-
ings indicate that PD-linked FBXO7 mutations aggravate
aggregation of FBXO7 proteins in mitochondria contrib-
uting to FBXO7-linked mitochondria proteotoxicity,
which is implicated in FBXO7 mutation induced DA
neuron degeneration in PD [26].
Impairment of UPS in PD pathogenesis was estab-
lished with mutations of Parkin, a HECT/RING hybrid
ubiquitin E3 ligase [27, 28], and other genetic forms of
PD [20, 29]. The impairment of UPS functions is also
implicated in DA neuron degeneration in SPD. The DA
in DA neurons can be an endogenous deleterious factor
to impair UPS function via irreversible conjugation of
protein cysteine residues by highly reactive DA oxidation
derived DA quinones [30, 31]. DA quinone is reported
to covalently modifies Parkin in living dopaminergic
cells, leading to Parkin insolubility and inactivation of its
E3 ubiquitin ligase function [32]. These findings show
vulnerabilities of Parkin and UPS to reactive DA
quinone, suggesting a mechanism for DA quinone in-
duced progressive UPS impairment and Parkin inhib-
ition in dopaminergic neurons during aging and SPD
[30–32].
FBXO7 and FBXO7-linked PARK15
The FBXO7 R378G mutation was first reported to be
linked to early-onset Parkinsonian (PARK15) in 2008
[33]. In 2009 R498X and T22M FBXO7 mutations were
subsequently indentified to induce autosomal recessive,
early-onset Parkinsonian-pyramidal syndrome [17, 33].
The PARK15 patients presented with Babinski signs and
spastic weakness [18, 34, 35]. Parkinsonism with resting
tremor, bradykinesia and postural instability developed
in later stages of some PARK15 patients [36]. Recently a
new FBXO7 L34R mutation causing typical L-dopa-
responsive Parkinsonism was reported in a Turkish
family [37]. The L34R mutation is similar to T22M mu-
tation, which is predicted to affect the UBL domain of
FBXO7 isoform 1 protein and is associated with dis-
turbed nuclear localization of FBXO7 protein [37]. An-
other heterozygous mutation (R481C) of FBXO7 was
reported in an Italian family [38, 39]. As these patients
also carried other genetic variants related to PD, the
pathogenicity of R481C FBXO7 mutant still remains to
be clarified [17, 18]. However a potential protective
Y52C FBXO7 polymorphism is recently identified [40].
The molecular structure of FBXO7 protein and PARK15
linked FBXO7 mutations or variations are summarized
in Fig. 1a.
FBXO7 proteins belongs to F-box-containing protein
family (FBP) [18, 35]. These FBP proteins possess a F-
box domain containing 40 amino acids [41, 42]. FBPs
assist in many important cell processes such as forma-
tion of protein complexes, maintenance of genome
stability, formation of synapse and circadian rhythms
[41, 42]. There are three kinds of FBP proteins: FBL
(FBP with F-box and leucine-rich-repeat domains), FBW
(FBP with F-box and WD40 domains) and FBXO pro-
teins (FBP with F-box domain only) [41, 42]. The
FBXO7 belongs to FBXO subfamily and have 5 function
domains (from N to C terminus): an UBL domain, a
cdk6 domain, a dimerization domain, a F-box domain
and a proline rich domain (Fig. 1) [35, 43]. WT FBXO7
proteins have two isoforms, isoform 1 has an UBL do-
main in its N terminus and is longer than isoform 2
(Fig. 1) [35, 43]. FBXO7 proteins are mainly expressed in
cerebral cortex, globus pallidum and SN, and to a lesser
extent in hippocampus and cerebellum [44]. Endogenous
and overexpressed FBXO7 proteins are mostly localized
to cell nucleus [36, 45]. FBXO7 proteins have been
found to be positively relevant to tumorigenesis [46].
FBXO7 proteins are reported to be required for the ubi-
quitination and proteasome-mediated proteolysis of the
hepatoma up-regulated protein (HURP), a regulator of
mitotic spindle assembly [47]. In SCFFBXO7 complex,
FBXO7 recruits HURP through its C-terminal proline-
rich region in a Cdk1-cyclin B-phosphorylation dependent
manner. Mutation of the multiple Cdk1-cyclin B phos-
phorylation sites on HURP or the proline-rich region of
FBXO7 abolishes the association between FBXO7 and
HURP [47]. Furthermore FBXO7 is reported to promote
ubiquitination and degradation of cIAP1, an inhibitor of
apoptosis family member which regulates canonical and
non-canonical NF-κB signalling [48]. Thus FBXO7 may
play roles in the regulation of cIAP1 function and cell
apoptosis via SCFFBXO7 ubiquitin E3 ligase mediated ubi-
quitination of cIAP1. Recently FBXO7 is found to interact
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with PI31, a proteasome inhibitor [49]. It is found that
there is a dimerization domain in both proteins, which is
vital to homodimerization or heterodimerization of
FBXO7 and PI31 proteins. However knockdown of
FBXO7 does not affect PI31 levels, arguing against PI31 as
a genuine substrate for SCFFBXO7 E3 ligase [49].
Recent findings demonstrate that FBXO7 is a stress re-
sponsive protein and stress of cells can up-regulate
FBXO7 expression [26]. The up-regulated expression of
WT FBXO7 can protect cells against stress [26]. How-
ever PD-linked FBXO7 mutants aggravate neurotoxins
induced cell demise [26]. Furthermore stress of cells can
promote mitochondria translocation of FBXO7 proteins
[26]. WT FBXO7 can facilitate neuroprotective mito-
phagy, whereas all PD-linked FBXO7 mutations inhibit
mitophagy [26]. The mitophagy is an important mito-
chondrial quality control process and functions to select-
ively clear away of damaged or impaired mitochondria
Fig. 1 Molecular structure and PD-linked generic variations of FBXO7 and Parkin. The molecular structures of FBXO7 (a) and Parkin (b) together
with indications of PD-linked mutations are respectively illustrated. The detailed sites of PD-linked generic variations of frameshift or missense
mutations of FBXO7 and Parkin are pointed with red or green colour arrows respectively
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by autophagy process, which was first mentioned by J.J.
Lemasters in 2005 [50]. The mitophagy promotes turn-
over of mitochondria and prevents accumulation of dys-
functional mitochondria which can lead to neuron
degeneration in PD and other human disorders [50]. It is
proposed that FBXO7 may participate in mitophagy
process via direct interactions with PINK1 and Parkin
[51, 52]. FBXO7 may modulate the translocation of
Parkin to damaged mitochondria [51]. Overexpression of
WT FBXO7, but not PD-linked FBXO7 mutants, can
rescue degeneration of DA neurons in Parkin null
Drosophila [51]. These findings suggest that FBXO7 may
function in a common pathway with Parkin/PINK1
protein pair to modulate mitophagy, whereas FBXO7
mutations lead to loss of these functions.
It is suggested by recent findings that WT FBXO7 pro-
tein can have dual protective as well as toxic functions
[26]. Stress of cells can up-regulate FBXO7 expression
to protect cells. However increased FBXO7 expression
under stress can lead to formation of deleterious FBXO7
protein aggregates, especially in mitochondria [26]. PD-
linked FBXO7 mutations aggravate toxic FBXO7 aggre-
gation in mitochondria [26]. FBXO7 aggregation in
mitochondria can impair mitochondria integrity, pro-
mote generation of reactive oxygen species (ROS) and
finally lead to cell demise [26]. However FBXO7 aggre-
gation induced proteotoxicity to cells can be alleviated
by protein aggregation inhibitors such as L-proline, but
be aggravated by prohibitin, a nature mitochondrial
protease inhibitor [26]. It is proposed that FBXO7 aggre-
gation, mitochondria impairment and ROS production
may form a positive feedback loop implicated in FBXO7-
linked neuron degeneration [26]. Such a situation can be
aggravated by FBXO7 mutations induced mitophagy
inhibition, contributing to PARK15 (Fig. 3) [26].
Parkin and Parkin-linked PARK2
Parkin mutations is a frequent cause of juvenile-
onset Parkinsonism (PARK2) with onset age < 40 years
[53, 54]. Parkin mutations have also been implicated
in late onset PD [55]. The PARK2 gene is the first
autosomal recessive Parkinsonism gene that has been
mapped and cloned [13, 16]. PD-Linked Parkin mutations
include deletions, multiplications and point mutations in
coding regions (Fig. 1b) [56]. Parkin mutations occur in
homozygotic, heterozygotic or compound heterozygotic
states, mostly in ring domains of Parkin [16, 57]. Several
Parkin mutations were identified in Parkin UBL domain
and also in unique Parkin domain (UPD) [58, 59]. Parkin
mutations induced PARK2 present with rigidity, bradyki-
nesia, dyskinesia, postural instability and dystonia [58–60].
Post-mortem studies revealed that most PARK2 patients
did not have Lewy bodies formation except in one case
where Lewy bodies were present in SN and locus
coeruleus districts [61]. The other cases of PARK2 had se-
vere loss of dopaminergic neurons in SN, Locus coeruleus,
and spinocerebellar system [58, 59]. Neurofibrillary tan-
gles can be also identified in cerebral cortex and brainstem
nucleus of PARK2 patients [62, 63].
Parkin is a HECT/RING hybrid ubiquitin E3 ligase
that physically receives ubiquitin on its catalytic centre
and then passes them onto its substrates. The N-
terminus of Parkin protein comprises of a UBL and a
UPD domains (Fig. 1). The C terminus of Parkin protein
consists of two RING fingers domains flanking a in-
between RING (IBR) domain (Fig. 1) [57, 62]. The UBL
domain is separated from UPD and RING-IBR-RING
domains by a linker that comprises of cleavage sites for
pro-apoptotic caspases [16, 57]. The UBL domain can
bind to subunits of 19S proteasome, which is supposed
to modulate proteasome function [62]. 2 RING domains
interact with ubiquitin E2 co-enzymes and substrates
to execute substrates ubiquitination [62]. Some stud-
ies also claim that UBL domain can also bind to sub-
strates [64]. WT Parkin is known to promote cellular
proliferation by association with several important cell
cycle regulatory molecules and exhibits tumour sup-
pressor effects [21, 56].
Parkin can recognize and interact with its specific
targets, execute its E3 ligase activity to promote ubi-
quitination and proteasomal degradation of its sub-
strates [65, 66]. In Parkin-linked PARK2, abnormal
accumulations or deregulation of some potential dele-
terious Parkin substrates are supposed to be relevant
to Parkin mutations induced DA neuron degeneration in
PD [20]. WT Parkin, but not PD-linked Parkin mutants,
can target and down regulate apoptosis inducing protein
Bax to abrogate Bax-induced apoptosis [67]. Thus Parkin
mutations may contribute to apoptosis via loss of control
on Bax induced toxicity. The Fas-associated factor 1
(FAF1) was a positive modulator for DA neuron degener-
ation in PD [68]. WT Parkin, but not PD-linked mutant
Parkin, can act as an E3 ubiquitin ligase to ubiquitinate
and degradate FAF1, thus abrogate FAF1-mediated
neuron cell demise [68]. Parkin can also target polygluta-
mine proteins ataxin-2 and ataxin-3 for ubiquitination to
negatively control their levels and reduce these polygluta-
mine proteins induced cytotoxicity [69, 70]. It is found
that α-Sp22 (a 22 KDa glycosylated form of α-syn) can be
a substrate of Parkin [71]. However in contrast to WT
Parkin, mutant Parkin failed to bind and ubiquitinate
α-Sp22 leading to pathological accumulation of α-Sp22 in
brain [71]. Other α-syn binding proteins including
synphilin-1 and some septins are also found to be
substrates of Parkin [72–76]. Co-expression of α-syn,
synphilin-1 and Parkin result in the formation of Lewy-
body-like ubiquitin-positive cytosolic inclusions [77]. In
this case Parkin is suggested to be a dual-function
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ubiquitin E3 ligase and that K63-linked ubiquitination of
synphilin-1 by Parkin may be involved in the formation of
Lewy body inclusions associated with PD [75]. Septins are
a group of GTP-binding proteins found primarily in
eukaryotic cells [78]. Septins have been implicated in the
localization of cellular processes at the site of cell division,
at the plasma membrane, at sites where specialized
structures like cilia or flagella are attached to the cell
body [79]. So far two septins (SEPT5/CDCrel-1 and
SEPT4/CDCrel-2) are found to be Parkin’s substrates
and may potentially play roles in PD pathogenesis [56].
The SEPT4/CDCrel-2 can coaggregate with α-syn as Lewy
bodies in PD, and increased level of SEPT5/CDCrel-1 can
rapidly eliminate DA neurons in rat heads [75]. Thus WT
Parkin may promote down regulation of SEPT4 and
SEPT5 to reduce these septins induced adverse impacts
on DA neuron viability. Parkin is also reported to target a
putative G protein-coupled transmembrane polypeptide,
named Pael receptor [80]. This receptor tends to become
unfolded, insoluble, and ubiquitinated in vivo and leads to
unfolded protein-induced cell death. Parkin specifically
ubiquitinates this receptor and promotes the degradation
of insoluble Pael receptor to suppress cell degeneration
[80]. Parkin is relevant to vesicle formation [81]. The
Synaptotagmin XI (important for vesicular trafficking
and dynamics) is reported to be a substrate of Parkin
[81]. The accumulation of Synaptotagmin XI was
found in SN of PD patients [81]. Since synaptotagmin
XI is a member of the synaptotagmin family that is
well characterized in their importance for vesicle for-
mation and docking, the interaction with this protein
suggests a role for Parkin in the regulation of the
synaptic vesicle pool and in vesicle release. Loss of
Parkin could thus affect multiple proteins controlling
vesicle pools, docking and release and explain the deficits
in dopaminergic function seen in PD patients with Parkin
mutations. Detailed Parkin substrates and their potential
implications in PD pathogenesis are discussed in a well-
written review paper [56].
On the other hand, Parkin can play important roles
in regulating mitochondrial movement, distribution,
and clearance [52, 82–86]. Parkin can cooperate with
PINK1 to control mitochondria quality via modulation
of mitophagy, whereas Parkin mutations impair mito-
phagy [52, 82, 83]. Upon mitochondria impairment,
PINK1 accumulates in defective mitochondria. The
accumulated PINK1 can attract Parkin from cytosol
and finally cooperatively mediate clearance of damaged
mitochondria via mitophagy. Indeed, activation and re-
cruitment of Parkin onto damaged mitochondria involves
PINK1-mediated phosphorylation of both Parkin and
ubiquitin (Ub). Through a stepwise cascade, Parkin is
converted from an autoinhibited enzyme into an active
phospho-Ub-dependent E3 ligase. After activation, Parkin
can ubiquitinate itself in concert with its many mitochon-
drial substrates. The PINK1 induced phosphorylation of
Ub conjugated to Parkin substrates can trigger further cy-
cles of Parkin recruitment and activation. This feed-
forward amplification loop regulates both Parkin activity
and mitophagy. It is identified that Parkin mediates the
formation of two distinct poly-ubiquitin chains, linked
through Lys-63 and Lys-27 [86]. The VDAC1 (voltage-
dependent anion channel 1) is recognized as a target for
Parkin-mediated Lys-27 poly-ubiquitylation and subse-
quent mitophagy induction [86]. Besides mitofusion 1
(Mfn1) and mitofusion 2 (Mfn2), large GTPases that medi-
ate mitochondrial fusion, can be substrates of Parkin for
mitophagy induction [84]. Parkin is also found to modulate
autophagy and mitophagy via mono-ubiquitination of
Bcl-2 [87]. Furthermore PINK1 and Parkin are also
reported to play role in arresting mitochondrial movement
via targeting Miro, a component of the primary motor/
adaptor complex that anchors kinesin to the mitochon-
drial surface [88]. PINK1 phosphorylates Miro and
phosphorylation of Miro activates proteasomal deg-
radation of Miro in a Parkin-dependent manner [88].
Removal of Miro from mitochondrion also detaches kine-
sin from its surface [88]. Thus by preventing mitochondrial
movement, the PINK1/Parkin pathway may quarantine
damaged mitochondria prior to their clearance via mito-
phagy [88]. The mitochondrial dynamin related protein-1
(Drp1) can also be the target of Parkin [85]. WT Parkin
interacts with and subsequently ubiquitinates Drp1 to
promote its proteasome-dependent degradation [85].
Pathogenic mutant Parkin inhibits the ubiquitination and
degradation of Drp1, leading to an increased level of Drp1
for mitochondrial fragmentation and cell viability impair-
ment [85].
Clinical aspects of Parkin and FBXO7 linked PD carriers
Homozygous or heterozygous mutations in Parkin and
FBXO7 are both associated with early onset autosomal
recessive Parkinsonism (PARK2 and PARK15). The com-
mon clinical features of PARK2 and PARK15 include
classic PD symptoms including rigidity, bradykinesia and
postural instability [89, 90]. In addition they have atyp-
ical features such as hyperreflexia, foot dystonia, sleep
benefit, diurnal fluctuations and early susceptibility to
levodopa induced dyskinesia [91]. Compared with
PARK2, the FBXO7-linked PARK15 progress more rap-
idly and is more severe. In PARK 15, Parkinsonism can
be accompanied with signs of cognitive decline, loss of
sustained levodopa responsiveness, severe levodopa in-
duced bradykinesia as well as pyramidal signs such as
hyperreflexia and babinski signs [15, 17]. PARK15 car-
riers also exhibit other signs such as eyelid aphaxia, slow
saccade and early imbalance in posture [92]. However
resting tremor is not a common feature of PARK 15
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[44]. We have analyzed and summarized the onset age
of PARK2 and PARK15 based on published reports [17,
18, 20–22, 51, 52, 54, 57, 58, 74–76, 78, 89]. About 38
cases of PARK2 and 9 cases of PARK15 patients with de-
tailed onset ages were analyzed (Table 1). After ANOVA
statistic analysis, we find that PARK15 has significant
earlier PD onset age than PARK2 (Table 1). Furthermore
it appears that PARK15 has a wider and more compli-
cated network of neuronal degeneration than PARK2
[36, 44].
Pathophysiologic aspects of Parkin and FBXO7 linked PD
There are overlapping and divergent pathophysiological
roles between Parkin and FBXO7. The physiological
roles of Parkin and FBXO7 are summarized in Fig. 2.
Both Parkin and FBXO7 play a common role in UPS
[35, 67, 98]. The Parkin is a HECT/RING hybrid ligase,
whereas FBXO7 is an adaptor protein in Skp-Cullin-
F-box (SCF) SCFFBXO7 ubiquitin E3 ligase complex
[12, 43]. Parkin and FBXO7 are both implicated in
tumorigenesis [51]. WT Parkin and FBXO7 can both be
cytoprotective, whereas their PD-linked mutants are all
deleterious to DA neurons. Both WT Parkin and FBXO7
promote mitophagy, whereas their PD-linked mutants
impair mitophagy. Furthermore FBXO7 and Parkin have
reciprocal interactions, suggesting overlaps of their signal-
ling pathways. WT FBXO7 but not PD-linked FBXO7
mutants can rescue lack of Parkin induced PD symptoms
in flies [51]. FBXO7 was reported to mediate mitochon-
dria translocation of Parkin [51]. Therefore FBXO7 may
act upstream of Parkin and have Parkin independent
complicated functions. Our recently findings show that
FBXO7 proteins can form deleterious aggregates in mito-
chondria [26]. However no reports have shown that
Parkin can form protein aggregates in mitochondria. The
similarities and differences of their pathophysiological
roles are summarized in Table 2.
Conclusions
Mutations of Parkin and FBXO7, two proteins in UPS,
are both implicated in pathogenesis of early onset DA
neuron degeneration in PD (PARK2 and PARK15). Both
WT Parkin and FBXO7 can facilitate, but their PD-
linked mutants impair neuroprotective mitophagy. How-
ever WT FBXO7 can have dual protective or deleterious
functions. FBXO7 proteins, especially PD-linked FBXO7
mutants, can form deleterious protein aggregates in
mitochondria under stress, leading to proteotoxic stress
in mitochondria. Taken together, FBXO7 mutations may
lead to neurodegeneration via impairment of UPS, inhib-
ition of mitophagy and formation of deleterious FBXO7
aggregates. On the other hand Parkin mutations may
induce neuron degeneration via impairment of UPS
together with inhibition of mitophagy (Fig. 3). The
Table 1 Onset ages of PARK2 and PARK15
PARK2 [15, 55, 58, 94–97] PARK15 [17, 18, 44, 45, 92]
Case no Ages Case no Ages
1 7 1 10
2 10 2 13
3 13 3 17
4 13 4 17
5 13 5 18
6 15 6 19
7 15 7 20
8 16 8 22






























Average ± SD 27.87 ± 13.37 17.78 ± 4.3*
*P = 0.032
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Fig. 2 Physiological roles of FBXO7 and Parkin in UPS. a, the physiological roles of FBXO7 in SCFFBXO7 E3 ligase complex. FBXO7 acts as an
adaptor protein to recognize and interact with its substrates for SCFFBXO7 E3 ligase mediated ubiquitination. After interaction with its substrates,
FBXO7 will bind with SKP1 which further interact with Cul1 and ROC1 to form functional SCFFBXO7 E3 ligase complex. The SCFFBXO7 E3 ligase will
mediate E2 ligase induced ubiquitination of FBXO7 substrates. b, the physiological roles of Parkin. After interaction with its substrates, Parkin
exerts its E3 ligase activity to mediate ubiquitination of its substrates by E2 ligase. c, detailed procedures of SCFFBXO7 and Parkin E3 ligases
mediated ubiquitination and proteasome degradation of substrates. (Left), SCFFBXO7 E3 ligase mediated substrates recognition, ubiquitination and
proteasomal degradation. (Right), Parkin mediated substrates recognition, ubiquitination and proteasomal degradation
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pathophysiologic variances between FBXO7 and Par-
kin can partially account for different clinical phe-
notypes of PARK15 and PARK2 (Fig. 3). Further
studies are needed to unravel the common patho-
physiologic links between these two proteins with
the hope to identify specific pathways for targeted
therapy in PD.
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